Inclusion Criteria:

- of either sex

- aged *15 and * 70 years

- never previously treated with radiotherapy, chemotherapy or surgery for malignant
disease (except neck adenectomy/diagnosis)

- with aWHO performance status * 2.

- amenable to regular follow-up

- capable of receiving chemotherapy and radiotherapy : in particular, with no
contraindications to the use of anthracyclines, bleomycin or cisplatinum.

- with informed consent at entry time, in writing or witnessed oral informed consent,
in accordance with local legislation requirements.

- Laboratory requirement : *Baseline hematologic status :

Neutrophil count * 2000 /mm3 Platelet count * 150,000 /mm3 Hemoglobin * 10 g / dl

Exclusion Criteria:

- Histologic types other than type II - III of the WHO classification

- T1 - T2 N0 - N1 or patients with metastatic

- Aged < 15 or > 70.

- Patients in whom chemotherapy is contraindicated: history of myocardial infarction
over the last 6 months before inclusion, or clinically present cardiac pathology.

- WHO Performance status >2

- History of prior malignancies (other than non melanoma skin cancer or excised
cervical carcinoma in situ).

- Uncontrolled infection,

- Patients refusing participation.

- Patients who, for social, familial or geographic reasons are unlikely to comply with
a long term follow-up.